The second generation of EORTC-ECIG experimental screening for systemic immunity adjuvants. Its significance for cancer immunotherapy. A comparison of BCG and its hydrosoluble extract.
作者信息
Mathe G, Halle-Pannenko O, Florentin I, Bruley-Rosset M, Kamel M, Hiu I J, Bourut C
出版信息
Eur J Cancer (1965). 1975 Nov;11(11):801-7. doi: 10.1016/0014-2964(75)90174-7.
PMID:767112
Abstract
摘要
相似文献
1
The second generation of EORTC-ECIG experimental screening for systemic immunity adjuvants. Its significance for cancer immunotherapy. A comparison of BCG and its hydrosoluble extract.欧洲癌症研究与治疗组织（EORTC）第二代系统性免疫佐剂的实验性筛选。其对癌症免疫治疗的意义。卡介苗及其水溶性提取物的比较。
Eur J Cancer (1965). 1975 Nov;11(11):801-7. doi: 10.1016/0014-2964(75)90174-7.
2
3
The use of systemic immunity adjuvants in the prophylaxis or therapy of cancer.全身免疫佐剂在癌症预防或治疗中的应用。
Johns Hopkins Med J Suppl. 1974;3:85-102.
4
5
An experimental screening for "systemic adjuvants of immunity" applicable in cancer immunotherapy.一项针对可应用于癌症免疫治疗的“全身性免疫佐剂”的实验性筛选。
Cancer Res. 1973 Sep;33(9):1987-97.
6
Immunotherapy of guinea pig cancer with BCG.用卡介苗对豚鼠癌症进行免疫治疗。
Johns Hopkins Med J Suppl. 1974;3:121-30.
7
Activated macrophages and the antitumor action of BCG.活化巨噬细胞与卡介苗的抗肿瘤作用
Natl Cancer Inst Monogr. 1973 Dec;39:127-33.
8
Experimental and clinical trials with BCG immunotherapy.卡介苗免疫疗法的实验和临床试验。
Johns Hopkins Med J Suppl. 1974;3:103-20.
9
Nonspecific macrophage activation by systemic adjuvants. Evaluation by lysosomal enzyme and in vitro tumoricidal activities.全身性佐剂对巨噬细胞的非特异性激活。通过溶酶体酶和体外杀肿瘤活性进行评估。
Int Arch Allergy Appl Immunol. 1976;51(5):594-607. doi: 10.1159/000231638.
10
In vivo and in vitro macrophage activation by systemic adjuvants.全身性佐剂对巨噬细胞的体内和体外激活作用。
Agents Actions. 1976 Feb;6(1-3):251-5. doi: 10.1007/BF01972217.
引用本文的文献
1
The permeability of tumour vessels.肿瘤血管的通透性。
Experientia. 1977 Jan 15;33(1):78-80. doi: 10.1007/BF01936765.
Zotero 插件